4523 Share Price Performance
JP¥0
-3926.00 (-100.00%)
Price JP¥0
Fair ValueJP¥5,076.92
Share Pricen/a
Narrative Update • May 19
Eisai Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
4523 Community Narratives
AN
Fair Value
·Fair Value JP¥5.08k 23.0% undervalued intrinsic discount
Global Alzheimer's Advances And Approvals Will Support Long-Term Expansion Prospects
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value JP¥3.67k 6.3% overvalued intrinsic discount
Japan HTA Review And MFN Proposals Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value JP¥6.2k 37.0% undervalued intrinsic discount
Aging Demographics And Early Diagnosis Will Drive Neurology Advancement
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Global Alzheimer's Advances And Approvals Will Support Long-Term Expansion Prospects
Eisai could benefit as simpler testing and clearer treatment pathways make it easier for more people with memory loss to get diagnosed and start its Alzheimer’s medicine. But the story hinges on that drug staying trusted, covered by insurers, and protected from price cuts and tougher competition.Read more
AN
JP¥5.08k
23.0% undervalued intrinsic discount
Fair Value
Revenue
4.32% p.a.
Profit Margin
7.95%
Future PE
22.12x
Price in 2029
JP¥5.84k
Aging Demographics And Early Diagnosis Will Drive Neurology Advancement
Key Takeaways Rapid adoption of LEQEMBI and ease of at-home dosing may make it the default treatment, significantly boosting revenue and market share. Streamlined operations and early-stage pipeline advances position Eisai for long-term profit growth and broader market leadership in neurology.Read more
AN
JP¥6.2k
37.0% undervalued intrinsic discount
Fair Value
Revenue
7.99% p.a.
Profit Margin
10.38%
Future PE
18.99x
Price in 2029
JP¥7.12k
Japan HTA Review And MFN Proposals Will Squeeze Margins
Key Takeaways Intensifying price pressures, patent losses, and heavy dependence on a narrow pipeline threaten revenue stability and make future earnings highly susceptible to disruption. Regulatory hurdles, market stagnation, and demographic trends pose serious long-term risks to growth, profitability, and competitive positioning.Read more
AN
JP¥3.67k
6.3% overvalued intrinsic discount
Fair Value
Revenue
0.98% p.a.
Profit Margin
6.55%
Future PE
21.8x
Price in 2029
JP¥4.22k
Trending Discussion
Recently Updated Narratives
AN
4523: Alzheimer’s And Oncology Pipeline Will Support Steady Future Returns
Fair Value: JP¥5.08k 23.0% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
4523: Subcutaneous Alzheimer’s Regimens Will Support Higher Earnings Quality And Future Share Returns
Fair Value: JP¥6.2k 37.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
4523: Future Alzheimer Dosing Approvals Will Still Not Justify Current Price
Fair Value: JP¥3.67k 6.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Eisai Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 03, 2026
- 136.78
- 76.83%
- 4.67%
- 20.1%
About 4523
- Founded
- 1941
- Employees
- 10917
- CEO
- WebsiteView website
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in India. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
